Breakthrough's Achilles Heel: Alexion’s Newly Acquired Kanuma Delayed By Manufacturing

FDA extends the PDUFA date for enzyme replacement therapy by three months so agency can review chemistry, manufacturing and controls information; another drug, Strensiq, is also pending at FDA without any action.